Meet Dr Josh Tobin, Lymphoma Researcher and inaugural Snowdome Foundation Haematology Fellow. Dr Tobin has a special interest in indolent lymphoma, a type of slow growing non-Hodgkin’s lymphoma. Although incurable, many of those diagnosed will not require treatment but for those who do, some will relapse and experience aggressive disease. The goal of Dr Tobin’s … Continued
Snowdome is very proud to continue our collaboration with the prestigious Leukemia & Lymphoma Society USA and Australia’s Leukaemia Foundation to fund Australian researchers and clinicians specialising in blood cancer research. Now entering our fourth year of funding, we are delighted to announce funding for two more ground-breaking projects into treating paediatric leukaemia and CAR … Continued
We are very pleased to announce that Snowdome, in conjunction with the Leukaemia Foundation, are funding RAVEN, a new, national paediatric trial for Australian children with relapsed or refractory acute lymphoblastic leukaemia (ALL). This is the first study of its kind to look at the effectiveness of a combination treatment to overcome chemotherapy resistance in … Continued
In 2010 chimeric antigen receptor T-cell (CAR T-cell) therapy was very experimental. It had only been tested in mice but two gentlemen who had nothing to lose opted for the experimental treatment. Remarkably the treatment worked and proved to be their cure from chronic lymphocytic leukaemia (CLL). A study that followed the two CLL patients … Continued
The results of ELARA, a large international trial investigating the treatment of relapsed or refractory follicular lymphoma (FL) with chimeric antigen receptor T-cell therapy (CART-cell) tisagenlecleucel have been published. A remarkable 69.1 per cent of patients treated with tisagenlecleucel had a complete response (no detectable disease) to treatment. Overall, 86.2 per cent of treated patients … Continued
Congratulations to the recipients of the 2021/22 Leukemia Lymphoma Society – Snowdome Foundation – Leukaemia Foundation (LLS-SF-LF) Translational Research Program grant winners. This year the grant is awarded to a multidisciplinary research team including, Dr Lev Kats at University of Melbourne, Prof Jake Shortt at Monash University, Prof Philip Thompson at Monash University and Assistant … Continued
Australia has been in an enviable position when it comes to COVID-19. We have been able to watch and learn from the Northern Hemisphere. Prof Miles Prince used this knowledge to indicate which blood cancer patient groups are most vulnerable to COVID-19. There are three main groups: 1. Chronic lymphocytic leukaemia (CLL) patients who are … Continued
With Australia opening up the risk of contracting COVID-19 rises. Cancer patients feel especially concerned. Prof Prince provides some advice on how to stay protected and what to do if you do get COVID-19. https://youtu.be/lIFt8Ks0JPo
Lymphoma is a blood cancer that develops when lymphocytes, part of your immune system, grow out of control. The problem with lymphoma is that cancer cells use the immune response to give them an extra advantage to go undetected and continue to replicate. The successful immune evasion by cancer cells means that the body is … Continued